ASCO GUIDELINES Bundle

Somatic Genomic Testing for Metastatic or Advanced Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475502

Contents of this Issue

Navigation

Page 1 of 15

2 Key Points ➤ An increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. ➤ All cancers with regulatory-approved biomarkers that guide therapy choice should undergo genomic sequencing. ➤ Multi-gene panel testing should be conducted whenever more than one genomic biomarker is linked to a regulatory agency-approved therapy in the patient's disease. ➤ Multi-gene panel testing is also beneficial when considering immunotherapies with genomic biomarker-linked site-agnostic approvals and to identify additional targets when there are few or no genotype-based therapy approvals for the patient's disease. ➤ Clinicians should consider the functional impact of the targeted alteration and the expected efficacy of genomic biomarker-linked- options relative to other treatments during treatment planning. ➤ Clinical trials are encouraged. ➤ Genomic sequencing should be performed within a certified laboratory.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Somatic Genomic Testing for Metastatic or Advanced Cancer